Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation of Proglucamune in the Treatment of Protective Qi Insufficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or females aged 18 to 65 years (inclusive) without regard to race or ethnic background~2. Provide a signed Informed Consent prior to entry in the study.~3. Willing to follow all study instructions and consume the assigned investigational product for 8 weeks.~4. Not currently taking a beta-glucan containing supplement or any other supplement that might interfere with the study design.~5. Ability to swallow tablets and pills.~6. Diagnosed as having Qi deficiency based on the following criteria:~   * exhibit a history of susceptibility to cold\* (\* as defined in Traditional Chinese Medicine, TCM)~  * exhibit a shortness of breath~  * exhibit a lack of energy or excessive fatigue~  * susceptible to spontaneous perspiration~  * exhibit a corpulent tongue with or without white fur~  * unwillingness to speak~  * weak or powerless pulse~  * pale complexion~Exclusion Criteria:~1. Persons diagnosed by TCM as having medical conditions other than low Qi.~2. Significant acute or chronic illness or other medical conditions that will prevent or interfere with giving an informed consent, or with participation in the study.~3. Persons with insulin-dependent and orally controlled diabetes will also be excluded from the study.~4. Scheduling difficulties or lack of transportation that will prevent or interfere with their ability to attend all of the necessary study visits.~5. Persons medically diagnosed with depression or anxiety disorders.~6. Persons with a history of alcohol abuse or other substance abuse within the previous 2 years.~7. Females who are attempting to become pregnant, pregnant, lactating or who have given birth within 1 year.~8. Persons who have had a medical surgery in the past 4 weeks.~9. Persons currently enrolled in a clinical trial, or who have completed a clinical trial within the last 4 weeks.~10. Allergies to mushrooms or other fungi.~11. Significant problems with constipation or diarrhea.~12. Persons exhibiting symptoms of cold\* (\*as defined by TCM) within the past 7 days.~13. A lifestyle or schedule incompatible with the study protocol.~14. Persons who are allergic to yeast products, have autoimmune disease/an immune disorder, or take antidepressants, blood thinners (anticoagulants), or immunosuppressant medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Proglucamune treatment (Type: EXPERIMENTAL): Participants were treated with 2 tablets of Proglucamune per day for a total duration of 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).